Overview

Preservation of Ovarian Function After Hematopoietic Cell Transplant

Status:
Terminated

Trial end date:
2015-04-01

Target enrollment:

Participant gender:

Summary

Women undergoing myeloablative allogeneic hematopoietic cell transplant (MA HCT) will receive GnRH agonist leuprolide. Women undergoing reduced intensity allogeneic (RIC) HCT will be observed.

Phase:

Phase 2

Details

Lead Sponsor:

Masonic Cancer Center, University of Minnesota

Collaborator:

Minnesota Medical Foundation

Treatments:

Leuprolide